<div id="readability-page-1"><p>Analyst Mathew Blackman of TD Cowen maintained a Buy rating on Tandem Diabetes Care, retaining the price target of $28.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Mathew Blackman has given his Buy rating due to a combination of factors that demonstrate strengthening fundamentals at Tandem Diabetes Care and a supportive outlook for growth. He highlights that first-quarter revenue surpassed expectations, driven by robust U.S. pump shipments and resilient international performance, even in the face of infusion set supply constraints that are likely to linger for a few more quarters.</p> <p>He also underscores that margins improved meaningfully, with adjusted EBITDA turning positive ahead of forecasts, despite only modest contribution so far from the shift to prescription and pharmacy channels, which should further enhance profitability over time. In addition, he points to the progressing Mobi tubeless product timeline, with a planned regulatory submission in 2026 and a staged commercial rollout thereafter, supporting an accelerating growth profile and margin expansion that he believes is not yet fully reflected in the current valuation, justifying his unchanged $28 price target and Buy recommendation.</p> <p>Blackman covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Orthofix Medical, and Tandem Diabetes Care. According to TipRanks, Blackman has an average return of <span>8.2%</span> and a 40.88% success rate on recommended stocks. </p> <p>In another report released on April 24, Rothschild &amp; Co Redburn also maintained a Buy rating on the stock with a $45.00 price target.</p></div>

TNDM

SBIO

LABU

<p>Analyst Mathew Blackman of TD Cowen has reaffirmed a Buy rating on Tandem Diabetes Care, maintaining a price target of $28. The decision is based on strengthening fundamentals, including first-quarter revenue exceeding expectations and improved margins. Despite supply constraints, the company shows a positive outlook with a planned regulatory submission for the Mobi tubeless product in 2026. Another report from Rothschild & Co Redburn also supports a Buy rating with a higher price target of $45.</p>

Tip Ranks

Tandem Diabetes

ALPS Medical Breakthrough

iShares US Medical Devices

iShares Biotechnology ETF

VanEck Biotech ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Zimmer Biomet

Orthofix

Buy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target Maintained